Immunotherapy: a glimmer of hope for metastatic prostate cancer

被引：15

作者：

Jindal, Vishal ^{[1
]}

机构：

[1] St Vincent Hosp, Dept Internal Med, 123 Summer St, Worcester, MA 01608 USA

来源：

CHINESE CLINICAL ONCOLOGY | 2018年 / 7卷 / 06期

关键词：

Immunotherapy; prostate cancer; sipuleucel-T; immune checkpoint inhibitors;

D O I：

10.21037/cco.2018.02.01

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer was the first cancer in which immunotherapy vaccine was approved by FDA in 2010 named Sipuleucel-T. No new immunotherapies have been approved since, as phase 3 trials didn't show any improvement in overall survival (OS) especially with immune checkpoint inhibitors. Currently tremendous amount of research is going on, in studying microenvironment of prostate cancer, finding new targets and biomarkers, and trying different combination therapies. Some of the new targets explored are VISTA and PARP inhibitors. Combination therapies have shown promising results in early phase trials and likely in near future we will have an effective immunotherapy for advanced prostate cancer. In this article we will review the current data and future of immunotherapy in prostate cancer.

引用

页数：11

共 68 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2] Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview [J].

Alme, Angela K. B. ;

Karin, Beerinder S. ;

Faltas, Bishoy M. ;

Drake, Charles G. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (04) :171-181

[3]

ANTONARAKIS ES, 2015, J CLIN ONCOL S, V33

[4] Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model [J].

Ardiani, Andressa ;

Farsaci, Benedetto ;

Rogers, Connie J. ;

Protter, Andy ;

Guo, Zhimin ;

King, Thomas H. ;

Apelian, David ;

Hodge, James W. .

CLINICAL CANCER RESEARCH, 2013, 19 (22) :6205-6218

[5] Clinical safety of a viral vector based prostate cancer vaccine strategy [J].

Arlen, Philip M. ;

Skarupa, Lisa ;

Pazdur, Mary ;

Seetharam, Mahesh ;

Tsang, Kwong Y. ;

Grosenbach, Douglas W. ;

Feldman, Jarett ;

Poole, Diane J. ;

Litzinger, Mary ;

Steinberg, Seth M. ;

Jones, Elizabeth ;

Chen, Clara ;

Marte, Jennifer ;

Parnes, Howard ;

Wright, John ;

Dahut, William ;

Schlom, Jeffrey ;

Gulley, James L. .

JOURNAL OF UROLOGY, 2007, 178 (04) :1515-1520

[6]

Beer TM, 2015, J IMMUNOTHER CANC S2, V3, P164

[7] Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer [J].

Beer, Tomasz M. ;

Kwon, Eugene D. ;

Drake, Charles G. ;

Fizazi, Karim ;

Logothetis, Christopher ;

Gravis, Gwenaelle ;

Ganju, Vinod ;

Polikoff, Jonathan ;

Saad, Fred ;

Humanski, Piotr ;

Piulats, Josep M. ;

Gonzalez Mella, Pablo ;

Ng, Siobhan S. ;

Jaeger, Dirk ;

Parnis, Francis X. ;

Franke, Fabio A. ;

Puente, Javier ;

Carvajal, Roman ;

Sengelov, Lisa ;

McHenry, M. Brent ;

Varma, Arvind ;

van den Eertwegh, Alfonsus J. ;

Gerritsen, Winald .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :40-+

[8] Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer [J].

Beer, Tomasz M. ;

Bernstein, Guy T. ;

Corman, John M. ;

Glode, L. Michael ;

Hall, Simon J. ;

Poll, Wayne L. ;

Schellhammer, Paul F. ;

Jones, Lori A. ;

Xu, Yi ;

Kylstra, Jelle W. ;

Frohlich, Mark W. .

CLINICAL CANCER RESEARCH, 2011, 17 (13) :4558-4567

[9] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[10] The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing [J].

Chakraborty, Mala ;

Wansley, Elizabeth K. ;

Carrasquillo, Jorge A. ;

Yu, Sarah ;

Paik, Chang H. ;

Camphausen, Kevin ;

Becker, Michael D. ;

Goeckeler, William F. ;

Schlom, Jeffrey ;

Hodge, James W. .

CLINICAL CANCER RESEARCH, 2008, 14 (13) :4241-4249

← 1 2 3 4 5 6 7 →